Cardioxyl Pharmaceuticals achieves positive results in first clinical study of CXL-1020 for ADHF

March 22, 2017

Dr. Garrie J. Haas, M.D., FACC, Section Director of Heart Failure/Transplant, and Medical Director of the Cardiovascular Clinical Research Organization, Professor of Medicine in the Division of Cardiovascular Medicine at The Ohio State University Medical Center and an investigator in the Cardioxyl Phase I/IIa trial stated, "There is currently a significant clinical need in the United States for a safe and effective therapy to treat the large population of hospitalized patients with heart failure. With its unique mechanism of action as compared to the limited options available on the market today, CXL-1020, if successful, will provide a novel and very useful new therapy for the treatment of these often severely ill patients."  

Cardioxyl Raises an Additional $15 Million in Funding

Cardioxyl also announced today that it has raised $15 million in funding from existing investors Aurora Funds and New Enterprise Associates (NEA).

Said Dr. Kroeger, "With this additional funding, Cardioxyl is well capitalized to execute on a Phase IIa trial for CXL-1020 and to continue development of our promising research portfolio. We are pleased to have the continued enthusiastic support of Aurora and NEA."

SOURCE Cardioxyl Pharmaceuticals, Inc.